Literature DB >> 14755723

Constitutive activation of MAPK cascade in acute quadriplegic myopathy.

Simone Di Giovanni1, Annamaria Molon, Aldobrando Broccolini, Gisela Melcon, Massimiliano Mirabella, Eric P Hoffman, Serenella Servidei.   

Abstract

Acute quadriplegic myopathy (AQM; also called "critical illness myopathy") shows acute muscle wasting and weakness and is experienced by some patients with severe systemic illness, often associated with administration of corticosteroids and/or neuroblocking agents. Key aspects of AQM include muscle atrophy and myofilament loss. Although these features are shared with neurogenic atrophy, myogenic atrophy in AQM appears mechanistically distinct from neurogenic atrophy. Using muscle biopsies from AQM, neurogenic atrophy, and normal controls, we show that both myogenic and neurogenic atrophy share induction of myofiber-specific ubiquitin/proteosome pathways (eg, atrogin-1). However, AQM patient muscle showed a specific strong induction of transforming growth factor (TGF)-beta/MAPK pathways. Atrophic AQM myofibers showed coexpression of TGF-beta receptors, p38 MAPK, c-jun, and c-myc, including phosphorylated active forms, and these same fibers showed apoptotic features. Our data suggest a model of AQM pathogenesis in which stress stimuli (sepsis, corticosteroids, pH imbalance, osmotic imbalance) converge on the TGF-beta pathway in myofibers. The acute stimulation of the TGF-beta/MAPK pathway, coupled with the inactivity-induced atrogin-1/proteosome pathway, leads to the acute muscle loss seen in AQM patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755723     DOI: 10.1002/ana.10811

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  32 in total

Review 1.  Persistent systemic inflammation in chronic critical illness.

Authors:  Christopher E Cox
Journal:  Respir Care       Date:  2012-06       Impact factor: 2.258

Review 2.  [Intensive care unit-acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy].

Authors:  K Judemann; D Lunz; Y A Zausig; B M Graf; W Zink
Journal:  Anaesthesist       Date:  2011-10       Impact factor: 1.041

Review 3.  Diagnosis of acute neuropathies.

Authors:  Clarissa Crone; Christian Krarup
Journal:  J Neurol       Date:  2007-09-21       Impact factor: 4.849

4.  Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy.

Authors:  Bertrand Léger; Romain Cartoni; Manu Praz; Séverine Lamon; Olivier Dériaz; Antoinette Crettenand; Charles Gobelet; Paul Rohmer; Michel Konzelmann; François Luthi; Aaron P Russell
Journal:  J Physiol       Date:  2006-08-17       Impact factor: 5.182

5.  Alterations in mRNA expression and protein products following spinal cord injury in humans.

Authors:  Maria L Urso; Yi-Wen Chen; Angus G Scrimgeour; Patrick C Lee; K Francis Lee; Priscilla M Clarkson
Journal:  J Physiol       Date:  2007-01-11       Impact factor: 5.182

6.  TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle.

Authors:  Yi-Ping Li; Yuling Chen; Joseph John; Jennifer Moylan; Bingwen Jin; Douglas L Mann; Michael B Reid
Journal:  FASEB J       Date:  2005-03       Impact factor: 5.191

7.  p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting.

Authors:  J M McClung; A R Judge; S K Powers; Z Yan
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-02       Impact factor: 4.249

8.  Identification of microRNAs involved in dexamethasone-induced muscle atrophy.

Authors:  He Shen; Teng Liu; Liangliang Fu; Shuhong Zhao; Bin Fan; Jianhua Cao; Xinyun Li
Journal:  Mol Cell Biochem       Date:  2013-05-29       Impact factor: 3.396

9.  Interleukin-1 stimulates catabolism in C2C12 myotubes.

Authors:  Wei Li; Jennifer S Moylan; Melissa A Chambers; Jeffrey Smith; Michael B Reid
Journal:  Am J Physiol Cell Physiol       Date:  2009-07-22       Impact factor: 4.249

10.  Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects.

Authors:  Andreas R Baudy; Erica K M Reeves; Jesse M Damsker; Christopher Heier; Lindsay M Garvin; Blythe C Dillingham; John McCall; Sree Rayavarapu; Zuyi Wang; Jack H Vandermeulen; Arpana Sali; Vanessa Jahnke; Stephanie Duguez; Debra DuBois; Mary C Rose; Kanneboyina Nagaraju; Eric P Hoffman
Journal:  J Pharmacol Exp Ther       Date:  2012-06-28       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.